ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,212.20
0.10%
S&P ASX All Technology
3,444.90
0.35%
Brent Oil
71.34
0.55%
US Dollar vs AUD
1.44788
-0.21%
Bitcoin
65,847.75
1.02%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Scholar Rock Holdings Corporation (SRRK) Share Price

Scholar Rock Holdings Corporation

Scholar Rock Holdings Corporation (SRRK)

NASDAQ
8.695
0.045
( 0.52% )
Updated: 03:16:37
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
8.695
Bid
8.69
Offer
8.70
Volume
207,961
8.60 Day's Range 8.88
6.225 52 Week Range 21.17
Market Cap
695.884M
Previous Close
8.65
Open
8.83
Last Trade
50
@
8.695
Last Trade Time
03:17:40
Financial Volume
US$ 1,824,773
VWAP
8.7746
Average Volume (3m)
691,257
Shares Outstanding
80,032,623
Dividend Yield
-
PE Ratio
-4.21
Earnings Per Share (EPS)
-2.07
Revenue
-
Net Profit
-165.79M

About Scholar Rock Holdings Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States.... Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.scholarrock.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Scholar Rock Holdings Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SRRK. The last closing price for Scholar Rock was US$8.65. Over the last year, Scholar Rock shares have traded in a share price range of US$ 6.225 to US$ 21.17.

Scholar Rock currently has 80,032,623 shares in issue. The market capitalisation of Scholar Rock is US$692.28 million. Scholar Rock has a price to earnings ratio (PE ratio) of -4.21.

Ask ADVFN Intelligence (AI)

SRRK Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

19 September 2024
Edgar (US Regulatory)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other...

14 September 2024
Business Wire

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Topline results expected in 2Q 2025 Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA...

10 September 2024
Business Wire

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...

04 September 2024
Business Wire

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...

29 August 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

20 August 2024
Edgar (US Regulatory)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other...

17 August 2024
Business Wire

Form 8-K - Current report

08 August 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

08 August 2024
Edgar (US Regulatory)

Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

- Remains on track to report topline data from pivotal Phase 3 SAPPHIRE trial in patients with Spinal Muscular Atrophy (SMA) in 4Q 2024 - New data from Phase 2 TOPAZ extension study in patients...

08 August 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.1852.173913043488.519.88.313571528.87166913CS
4-0.655-7.005347593589.359.87.958099548.68264952CS
120.98512.7756160837.719.957.536912578.86955368CS
26-6.465-42.645118733515.1617.97.5380347010.44625734CS
521.93528.6242603556.7621.176.22586267212.49252968CS
156-24.425-73.746980676333.1236.434.32556658110.89096348CS
260-1.035-10.63720452219.73704.32550736818.97581625CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CNEYCN Energy Group Inc
US$ 1.011
(74.34%)
198.98M
UXINUxin Ltd
US$ 4.56
(61.13%)
11.64M
ONCOOnconetix Inc
US$ 5.26
(56.76%)
31.51M
JFU9F Inc
US$ 1.78
(35.88%)
178.56k
CUECue Biopharma Inc
US$ 0.6113
(34.62%)
1.93M
EDBLEdible Garden AG Inc
US$ 0.28
(-39.81%)
4.21M
ICGIntchains Group Ltd
US$ 5.60
(-33.96%)
2.04M
NVNOenVVeno Medical Corporation
US$ 3.3901
(-24.66%)
1.65M
HUBCWHub Cyber Security Ltd
US$ 0.0093
(-21.85%)
18.57k
IVPInspire Veterinary Partners Inc
US$ 0.4713
(-21.32%)
3.14M
XPONExpion360 Inc
US$ 0.0803
(24.69%)
217.65M
CNEYCN Energy Group Inc
US$ 1.011
(74.34%)
198.98M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.153
(12.01%)
189.58M
NVDANVIDIA Corporation
US$ 120.7064
(-2.69%)
160.12M
SQQQProShares UltraPro Short QQQ
US$ 7.41
(1.23%)
85.48M

SRRK Discussion

View Posts
Monksdream Monksdream 3 weeks ago
SRRK under $10
👍️0
Monksdream Monksdream 2 months ago
SRRK under $10
👍️0
Monksdream Monksdream 3 months ago
SRRK under $10
👍️0
retireat40 retireat40 12 months ago
Wow. Now a $7 stock
👍️0
georgie18 georgie18 3 years ago
SRRK...$34.75...on the 100ma break...:party:
[11:57 AM]
georgie18 — 10/29/2021
SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...:party:
👍️0
georgie18 georgie18 3 years ago
SRRK...$28.45...Lets see if we can Break/Hold the Upper Band today...as the Bollie Squeeze sets up here...imo...We shall see...:party:
[4:32 AM]
georgie18 — 10/29/2021
SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...:party:
👍️0
georgie18 georgie18 3 years ago
SRRK...$27.34...Bullish Doji Star Reversal Pattern to the Upside as the Psar flipped Bullish...

Pincher Squeeze in play here...as the MACD Crosses Positive...Looking for a $40 Break/Hold...imo...we shall see...

Played this in the spring for nice profits...Back in again on this Pattern...

Chart... https://schrts.co/HtbEtPcc ...
👍️0
georgie18 georgie18 3 years ago
SRRK...$31.62...on the 50ma Break to the Upside...:party:
[6:26 AM]
georgie18 — 05/24/2021
SRRK...$28.75...Took a starter on the Bullish Harami today...:party:
👍️0
georgie18 georgie18 3 years ago
SRRK...$29.69...in the P/M...https://finance.yahoo.com/news/scholar-rock-presents-topaz-phase-113000823.html ...:party:
👍️0
stockguard stockguard 3 years ago
We`ll be back to higher highs soon.
👍️0
georgie18 georgie18 3 years ago
SRRK...$28.75...Took a starter on the Bullish Harami today...CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for apitegromab, a selective inhibitor of myostatin activation, for the treatment of patients with Spinal Muscular Atrophy (SMA). Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and get new drugs to patients earlier. Through Fast Track, Scholar Rock is eligible to submit a rolling Biologic License Application (BLA) for apitegromab if relevant criteria are met...
👍️0
stockguard stockguard 3 years ago
Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy
https://www.businesswire.com/news/home/20210524005771/en/
👍️0
stockguard stockguard 3 years ago
Scholar Rock weakness overdone after TOPAZ results, says JPMorgan
JPMorgan analyst Anupam Rama noted that Scholar Rock shares are down about 15%, which Rama views as "overdone," after the company announced update 12-month results from the phase 2 TOPAZ study in the treatment of Type 2/3 Spinal Muscular Atrophy. The 12-month data showed relatively consistent functional benefit compared to six-month interim data reported in October, noted Rama, who added that "there were no major concerns" on the safety front. The analyst, who sees the "totality of data as a probability of success increase lever," reiterates an Overweight rating on Scholar Rock shares.
👍️0
georgie18 georgie18 4 years ago
SRRK...$48.08...Back in on the Bullish Engulfing Candle on the Overbought Retrace...Psar will flip to a Bullish Buy Position this week...

Break/Hold $52 with no topside resistance and we make a run at $75/$100 range on this Blue Skies Chart...imo...we shall see...

Chart..https://schrts.co/wGhsGXPZ

georgie18 Wednesday, 10/28/20 06:38:13 AM
Re: None 0
Post #
3
of 21
SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
[6:37 AM]
georgie1808/10/2020
SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...

👍️0
georgie18 georgie18 4 years ago
SRRK...$46.91...Looking for the Upper Bollie breakout...on the Pole N Flag Breakout...imo...we shall see...

georgie18 Tuesday, 11/24/20 07:16:17 AM
Re: georgie18 post# 3 0
Post #
19
of 20
SRRK...$41.40...Bullish Pole N Flag Breakout setting up here as the Bollies start to Squeeze here...Looking for $75/$100 move...imo...we shall see...

Chart... http://schrts.co/rzYtEpQt

georgie18 Wednesday, 10/28/20 06:38:13 AM
Re: None 0
Post #
3
of 19
SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
[6:37 AM]
georgie1808/10/2020
SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...
👍️0
georgie18 georgie18 4 years ago
SRRK...$46.91...on the Upper Bollie Break...
👍️0
georgie18 georgie18 4 years ago
SRRK...$41.40...Bullish Pole N Flag Breakout setting up here as the Bollies start to Squeeze here...Looking for $75/$100 move...imo...we shall see...

Chart... http://schrts.co/rzYtEpQt

georgie18 Wednesday, 10/28/20 06:38:13 AM
Re: None 0
Post #
3
of 19
SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
[6:37 AM]
georgie1808/10/2020
SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...

👍️0
JohnQQ JohnQQ 4 years ago
https://finance.yahoo.com/m/9fae2849-74b9-3d45-9293-6540a970693d/2-top-biotech-stocks-from-the.html
👍️0
JohnQQ JohnQQ 4 years ago
New Seeking Alpha Article
👍️0
JohnQQ JohnQQ 4 years ago
SOME SHORTS DID NOT CLOSE HAHA !

https://seekingalpha.com/article/4384830-scholar-rock-is-phase-2-1-billion-is-too-expensive
👍️0
Pedro2004 Pedro2004 4 years ago
I think the run is over.
They just did a Private Placement at $39.00
Let's see what happens in a few months.
👍️0
TheFinalCD TheFinalCD 4 years ago
$41's wow CONGRATS to anyone making money here


SRRk
👍️0
Pedro2004 Pedro2004 4 years ago
Thanks. This company woke up very quickly.
👍️0
ClayTrader ClayTrader 4 years ago
* * $SRRK Video Chart 10-29-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
georgie18 georgie18 4 years ago
SRRK...$43.43...CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share...

No position at the moment after the $11 range alert ran to $45 range...
👍️0
ClayTrader ClayTrader 4 years ago
* * $SRRK Video Chart 10-28-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
easymoney easymoney 4 years ago
Sold before eod lol well traded like 10 times today and yesterday
👍️0
PAC PAC 4 years ago
Book runners pumping to short shares to absorb the offering at a lower price. $150m worth will be a lot of shares for them to accumulate short. that's why the run up and squeeze.

Seems like co. desperate for money bc the results were interim of phase 2. maybe get a pricing below $30
👍️0
TheFinalCD TheFinalCD 4 years ago
45.30 CONGRATS!!!


SRRK
👍️0
TheFinalCD TheFinalCD 4 years ago
SRRK $40 BROKE!!


42.11 HOD


👍️0
Pedro2004 Pedro2004 4 years ago
Let's see if this breaks $40.00 today.
👍️0
Pedro2004 Pedro2004 4 years ago
I agree. I was watching this since yesterday, In at 23, out at 24.50.

👍️0
georgie18 georgie18 4 years ago
SRRK...$34.85...in the PM...on this Blue Skies Chart set up...no topside resistance here...
[6:37 AM]
georgie1808/10/2020
SRRK...$14.22...Hod...just keeps gradually moving up off my $11.29 alert...I think $31 is coming here...we shall see...
👍️0
Jornwell Jornwell 4 years ago
Dilution always kills at this pps, look at DRYS I would stay away for now unless TA shows uptick in buying activity
👍️0
ASPD_Capital ASPD_Capital 4 years ago
Spinal Muscular Atrophy (SMA) affects between 1 in 6,000 to 1 in 10,000 depending on type. $SRRK tested SRK-015 on 58 people and they improved a little. Still a ways to go for a marginally rare disease. At the same time, the company announced intent to issue $150 million worth of new shares at an undisclosed price with a $22.5 million option. Please post your thoughts on whether this price action continues or if dilution and loss of interest tanks it. I'm definitely torn. LOL
👍️0

Your Recent History

NASDAQ
SRRK
Scholar Rock
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved